Celgene says it has raised the top dose and expanded its trial of its anti-BCMA CAR-T candidate for myeloma licensed from Bluebird Bio, but the company still thinks it’s on course for approval in 2020.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,